SEC Form S-8 filed by Dianthus Therapeutics Inc.
As filed with the Securities and Exchange Commission on August 8, 2024
Registration No. 333-
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 |
||||
|
|
|
|
|
|
|
|
|
|
FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 |
||||
|
|
|
|
|
|
|
|
|
|
Dianthus Therapeutics, Inc. |
||||
(Exact name of registrant as specified in its charter) |
||||
|
|
|
|
|
|
Delaware |
|
81-0724163 |
|
|
(State or Other Jurisdiction of Incorporation or Organization |
|
(I.R.S. Employer Identification No.) |
|
|
|
|
|
|
|
|
|
|
|
|
7 Times Square, 43rd Floor New York, NY 10036 |
|
||
|
(Address of Principal Executive Offices, Zip Code) |
|
||
|
|
|
|
|
|
|
|
|
|
Second Amended and Restated Dianthus Therapeutics, Inc. Stock Option and Incentive Plan |
||||
|
|
(Full title of the plan) |
|
|
|
|
|
|
|
|
|
|
|
|
Adam M. Veness, Esq. Senior Vice President, General Counsel and Secretary Dianthus Therapeutics, Inc. 7 Times Square, 43rd Floor New York, NY 10036 (929) 999-4055 |
||||
|
|
|
|
|
|
|
Copies to: |
|
|
Ryan A. Murr, Esq. Branden C. Berns, Esq. Chris W. Trester, Esq. Gibson, Dunn & Crutcher LLP One Embarcadero Center, Suite 2600 San Francisco, CA 94111 Telephone: (415) 393-8200 Facsimile: (415) 393-8306 |
||||
|
|
|
|
|
|
|
|
|
|
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. |
Large accelerated filer |
☐ |
|
Accelerated filer |
☐ |
Non-accelerated filer |
☒ |
|
Smaller reporting company |
☒ |
|
|
|
Emerging growth company |
☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐ |
EXPLANATORY NOTE
This Registration Statement on Form S-8 (this “Registration Statement”) registers an additional 2,931,820 shares of common stock, $0.001 par value per share (“Common Stock”), of Dianthus Therapeutics, Inc. (the “Registrant”) available for issuance under the Second Amended and Restated Dianthus Therapeutics, Inc. Stock Option and Incentive Plan (the “Incentive Plan”), which was adopted by the Registrant’s board of directors on March 14, 2024 and approved by the Registrant's stockholders on May 23, 2024 to amend and restate the Amended and Restated Dianthus Therapeutics, Inc. Stock Option and Incentive Plan.
The additional shares are of the same class as other securities relating to the Incentive Plan for which the Registrant’s registration statement filed Form S-8 filed with the Securities and Exchange Commission (the “SEC”) on March 21, 2024, October 4, 2023, March 8, 2022, March 3, 2021, March 3, 2020, March 19, 2019, and June 22, 2018 (Registration Nos. 333-278151, 333-274865, 333-263358, 333-253815, 333-236853, 333-230387, and 333-225838), and which, together with all exhibits filed therewith or incorporated therein by reference, are hereby incorporated by reference pursuant to General Instruction E to Form S-8 and the shares of Common Stock registered hereunder with respect to the Incentive Plan are in addition to the shares of Common Stock registered on such registration statements.
PART I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
Item 1. Plan Information
The documents containing the information specified in Part I of this Registration Statement will be delivered to employees as specified by Rule 428(b)(1) of the Securities Act of 1933, as amended (the “Securities Act”). In accordance with the instructions to Part I of Form S-8, such documents are not being filed with the SEC either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities Act. Such documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of Form S-8, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 8. Exhibits.
Exhibit Number |
|
Description |
4.1 |
|
|
4.2 |
|
|
5.1* |
|
|
23.1* |
|
Consent of Deloitte & Touche LLP, independent registered public accounting firm |
23.2* |
|
Consent of Gibson, Dunn & Crutcher LLP (included in Exhibit 5.1) |
24.1* |
|
Power of Attorney (included on the signature page to this Registration Statement) |
99.1 |
|
|
107.1* |
|
* Filed herewith.
Item 9. Undertakings.
(a) The undersigned Registrant hereby undertakes:
(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.
(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
(b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(h) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
SIGNATURES
Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on August 8, 2024.
|
DIANTHUS THERAPEUTICS, INC. |
|
|
|
|
|
By: |
/s/ Ryan Savitz |
|
Name: |
Ryan Savitz |
|
Title: |
Chief Financial Officer and Chief Business Officer |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints each of Marino Garcia, Ryan Savitz and Adam Veness and each of them acting individually, as his or her true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution in each of them singly, for him or her and in his or her name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the SEC, granting to the attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in or about the premises, as full to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that the attorneys-in-fact and agents or any of each of them or their substitutes may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities indicated on the dates indicated.
Signature |
|
Title |
Date |
|
|
|
|
/s/ Marino Garcia |
|
Chief Executive Officer, President and Director |
August 8, 2024 |
Marino Garcia |
|
(Principal Executive Officer) |
|
|
|
|
|
/s/ Ryan Savitz |
|
Chief Financial Officer and Chief Business Officer |
August 8, 2024 |
Ryan Savitz |
|
(Principal Financial Officer) |
|
|
|
|
|
/s/ Edward Carr |
|
Chief Accounting Officer |
August 8, 2024 |
Edward Carr |
|
(Principal Accounting Officer) |
|
|
|
|
|
/s/ Alison F. Lawton |
|
Director and Chair of the Board |
August 8, 2024 |
Alison F. Lawton |
|
|
|
|
|
|
|
/s/ Tomas Kiselak |
|
Director |
August 8, 2024 |
Tomas Kiselak |
|
|
|
|
|
|
|
/s/ Anne McGeorge |
|
Director |
August 8, 2024 |
Anne McGeorge |
|
|
|
|
|
|
|
/s/ Leon O. Moulder, Jr. |
|
Director |
August 8, 2024 |
Leon O. Moulder, Jr. |
|
|
|
|
|
|
|
/s/ Paula Soteropoulos |
|
Director |
August 8, 2024 |
Paula Soteropoulos |
|
|
|
|
|
|
|
/s/ Jonathan Violin |
|
Director |
August 8, 2024 |
Jonathan Violin |
|
|
|